Inotek Pharmaceuticals was founded in 1996 and is headquartered in Lexington, US

Inotek Pharmaceuticals has an office in Lexington

Lexington, US (HQ)

33 Hayden Avenue

USD

## Net income (Q1, 2017) | (10.7 m) |

## EBIT (Q1, 2017) | (10 m) |

## Market capitalization (18-Aug-2017) | 18 m |

## Cash (31-Mar-2017) | 25.3 m |

Inotek Pharmaceuticals's current market capitalization is $18 m.

- Source: SEC Filings

USD | FY, 2015^{} | FY, 2016^{} |
---|---|---|

## R&D expense | (12.6 m) | (32 m) |

## General and administrative expense | (7.8 m) | (9.9 m) |

## Operating expense total | (20.4 m) | (41.9 m) |

## EBIT | (20.4 m) | (41.9 m) |

## Interest expense | (1.2 m) | (1.4 m) |

## Interest income | 89 k | 443 k |

## Net Income | (68 m) | (42.9 m) |

USD | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|

## R&D expense | (1.1 m) | (2 m) | (3.6 m) | (7.6 m) | (6.5 m) | (8.4 m) | (7.1 m) |

## General and administrative expense | (2 m) | (1.7 m) | (1.8 m) | (2.5 m) | (2.3 m) | (2.3 m) | (2.9 m) |

## Operating expense total | (3 m) | (3.7 m) | (5.4 m) | (10.1 m) | (8.8 m) | (10.7 m) | (10 m) |

## EBIT | (3 m) | (3.7 m) | (5.4 m) | (10.1 m) | (8.8 m) | (10.7 m) | (10 m) |

## Interest expense | (474 k) | (564 k) | (192 k) | (474 k) | (564 k) | (525 k) | (876 k) |

## Interest income | 33 k | 69 k | 96 k | 120 k | 172 k | ||

## Net Income | (1.5 m) | (2.8 m) | (56 m) | (10.1 m) | (18.8 m) | (29.9 m) | (10.7 m) |

- Source: SEC Filings

USD | FY, 2015^{} | FY, 2016^{} |
---|---|---|

## Cash | 80 m | 29.8 m |

## Inventories | 1.1 m | 1.9 m |

## Current Assets | 112.4 m | 128.3 m |

## PP&E | 812 k | 1.1 m |

## Total Assets | 113.3 m | 129.6 m |

## Accounts Payable | 1.6 m | 1.6 m |

## Current Liabilities | 4.1 m | 7.2 m |

## Total Liabilities | 56.5 m | |

## Additional Paid-in Capital | 304.6 m | 311.8 m |

## Retained Earnings | (196 m) | (238.9 m) |

## Total Equity | 108.8 m | 73.2 m |

## Financial Leverage | 1 x | 1.8 x |

USD | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|

## Cash | 53.1 m | 49 m | 89.2 m | 58.7 m | 38.5 m | 83 m | 25.3 m |

## Current Assets | 53.4 m | 49.5 m | 119.2 m | 103.2 m | 98.7 m | 138.9 m | 116.6 m |

## PP&E | 29 k | 756 k | 790 k | 976 k | 1 m | 1.1 m | |

## Total Assets | 55.5 m | 51.7 m | 120.1 m | 104.2 m | 99.9 m | 140.1 m | 117.9 m |

## Accounts Payable | 1.3 m | 813 k | 1.7 m | 1.4 m | 921 k | 1.8 m | 1.9 m |

## Current Liabilities | 2.5 m | 2.5 m | 3.2 m | 4.6 m | 4.1 m | 5.9 m | 5.3 m |

## Additional Paid-in Capital | 163.3 m | 163.4 m | 304.1 m | 305.1 m | 309.9 m | 310.7 m | 312.6 m |

## Retained Earnings | (129.5 m) | (131.9 m) | (187.9 m) | (206.1 m) | (214.8 m) | (225.9 m) | (249.5 m) |

## Total Equity | 34 m | 31.7 m | 116.5 m | 99.2 m | 95.4 m | 85.1 m | 63.3 m |

## Financial Leverage | 1.6 x | 1.6 x | 1 x | 1.1 x | 1 x | 1.6 x | 1.9 x |

USD | FY, 2015^{} | FY, 2016^{} |
---|---|---|

## Net Income | (68 m) | (42.9 m) |

## Depreciation and Amortization | 45 k | 169 k |

## Accounts Payable | 487 k | (41 k) |

## Cash From Operating Activities | (17.4 m) | (37.3 m) |

## Purchases of PP&E | (412 k) | (487 k) |

## Cash From Investing Activities | (31.7 m) | (66.1 m) |

## Short-term Borrowings | (5.8 m) | (5.8 m) |

## Cash From Financing Activities | 125.5 m | 53.1 m |

## Interest Paid | 89 k | 89 k |

USD | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|

## Net Income | (1.5 m) | (2.8 m) | (56 m) | (10.1 m) | (18.8 m) | (29.9 m) | (10.7 m) |

## Depreciation and Amortization | 6 k | 37 k | 72 k | 111 k | 61 k | ||

## Accounts Payable | 154 k | (333 k) | 563 k | (257 k) | (712 k) | 144 k | 310 k |

## Cash From Operating Activities | (2 m) | (6.1 m) | (10.4 m) | (9 m) | (17 m) | (26.1 m) | (11.6 m) |

## Purchases of PP&E | (30 k) | (318 k) | (15 k) | (236 k) | (344 k) | (53 k) | |

## Cash From Investing Activities | (30 k) | (29.4 m) | (12.3 m) | (28.7 m) | (23.8 m) | 7.1 m | |

## Short-term Borrowings | (5.8 m) | (5.8 m) | (5.8 m) | (5.8 m) | (5.8 m) | ||

## Cash From Financing Activities | 51.5 m | 51.5 m | 125.4 m | 51.5 m | 4.2 m | 52.9 m | |

## Interest Paid | 89 k | 89 k | 89 k | 89 k | 89 k | 89 k | 1.5 m |

Y, 2017 | |
---|---|

## Financial Leverage | 1.9 x |